Vicadrostat by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval

Vicadrostat is under clinical development by Boehringer Ingelheim International and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure).

Early Detection and Gender Disparities in COPD

In this interview, Dr. MeiLan Han, a distinguished pulmonologist and Chief of the Division of Pulmonary and Critical Care at the University of Michigan, shares her

November 14, 2023

A Biological Framework for Multiple Sclerosis

A biological, mechanism-based framework to reclassify multiple sclerosis (MS) types was proposed by the International Advisory Committee on Clinical Trials in Multiple Sclerosis. The approach

May 1, 2024

Reinforcement learning improves performance of AI-based skin cancer diagnosis

Artificial intelligence (AI) is already being used to diagnose skin cancer, but it cannot (yet) keep pace with the complex decision-making of doctors in practice.

July 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.